RESULTS
Females accounted for 50.2 % of the our patients and their mean age was 47.98 ± 14.81 (19-88) years. 14.3% (n: 45) of the individuals were 65 years of age and older, 34.3% (n: 108) had no findings in their lung computed tomography (CT) and chest X-rays. 20.6% (n: 65) of our patients were smoking and 70.2% (n: 221) of our patients were treated at home. 133 patients had at least one comorbid disease. Hypertension (HT) was determined in 43 patients, asthma was determined in 29 patients, diabetes mellitus (DM) was determined in 25 patients, coronary artery disease (CAD) was determined in 15 patients, chronic obstructive pulmonary disease (COPD) was determined in 12 patients, neurological disease was determined in 7 patients, a history of malignancy was determined in 7 patients (2 patients with lung cancer , 3 patients with thyroid cancer, 1 patient with brain cancer, 1 patient with osteosarcoma), hypothyroidism was determined in 5 patients, rheumatological disease was determined in 4 patients, renal failure 3 patients and bronchiectasis was determined in 3 patients. In addition to treatment with Favipiravir and/or Hydroxychloroquine, 47 patients received empiric antibiotic therapy, 33 patients received corticosteroid therapy and 23 patients received both antibiotic and corticosteroid therapy. 119 patients received prophylactic enoxaparin and 4 patients received enoxaparin at the therapeutic dose.
General characteristics of the study group are presented in Table 1.
When the symptoms of the study group were evaluated, while 7% (n: 22) of the subjects were asymptomatic in the first part of the study, 27.3% (n: 86) of the subjects were found to be asymptomatic in the 1-month period (p<0.001). It was found that the symptoms of fever, myalgia, diarrhea, dyspnea, cough, loss of taste and smell and sore throat decreased within 1 month of the first period when the contrast of the two periods was examined (Table 2). The symptom distribution of the study group by period is shown in Table 2.
The median lymphocyte percent was 26.00 (17.75-33.50) in the first part of the analysis, and 27.00 (21.20-34.20) in the calculation one month later, when certain laboratory values of the study group were analyzed, and there was no difference between the two times. On the other hand, although the values of neutrophils, neutrophils/lymphocytes (NLR) and C-reactive proteins (CRP) decreased over time, the values of platelets and D-dimers increased (Table 3). The distribution of such laboratory values by time is shown in Table 3.
In our study, no statistically significant difference was found between age, gender and smoking status (p>0.005 for each) when the distribution of individuals with persistent symptoms was examined after 1 month. It was determined that the symptoms had persisted in patients who had been hospitalized, had dual therapy, had comorbid diseases and had more common pathologies in their pulmonary imagings (Table 4).
182 patients had no comorbidities, 115 of those without comorbidity continued to have symptoms in the first month. 114 of those with comorbid diseases continued to have symptoms in the first month. Table 4 describes the distribution of general characteristics of the study group according to the occurrence of symptoms after 1 month.
Although there were no symptoms in 7 patients received antibiotic therapy and in 1 patient received antibiotic and corticosteroid therapy in the first month, all patients received corticosteroid therapy had at least one symptom in the first month (p<0.001).
Initial D-dimer, initial CRP and the values of platelet, D dimer and CRP in the first month were detected to be higher in patients with persistens symptoms when the laboratory values of patients whose symptoms continue after 1 month were examined. No difference was found between the values of initial Neutrophil%, Lymphocyte% and NLR and the first month (Table 5).
The distribution of laboratory values for the study group based on the presence of symptoms after 1 month is shown in Table 5.
When the laboratory values of the individuals according to the treatment received in our study were examined; only those receiving hydroxychloroquine had lower initial D-dimer, 1st month lymphocyte and 1st month D-dimer levels, whereas those undergoing dual therapy had higher 1st month CRP levels. (Table 6). In the subgroup analysis, no statistically difference was found in the initial and 1st month NLR values. The distribution of laboratory values by treatment received by the research group is shown in Table 6.